Scholarlink

<p>Disulfidptosis is characterized by the aberrant collapse of disulfide bonds in actin cytoskeleton proteins and F-actin. This study aims to explore the potential of disulfidptosis-related genes (DRGs) as biomarkers and targets for myocardial infarction (MI). Eight of the 24 DRGs differently expressed in the peripheral blood samples of MI patients compared to healthy people; five of the differently expressed DRGs (TLN1, SLC3A2, NDUFA11, FLNA and CD2AP) had tolerable diagnostic capabilities and were identified as the marker DRGs of MI; the marker DRGs played a vital role in immune response, inflammatory reaction, and energy metabolism. Some of the marker DRGs were correlated with several immune cells that were involved in MI. NV-128, ME-344 and metformin hydrochloride potentially target NDUFA11; IGN523 potentially target SLC3A2; and simufilam potentially target FLNA. DRGs might have potential in diagnosing MI, and targeting disulfidptosis might offer potential therapeutic value for MI.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Identification of potential biomarkers and targets for myocardial infarction via genetic analysis of disulfidptosis-related genes

  • 期刊论文

  • 发表日期：

    2026年2月17日

查看全文
  • Ming-Rui Li,
  • Li-Qun Lu,
  • Xiu-Ju Luo,
  • Zhi-Jun Zhou,
  • Jun Peng

摘要

Disulfidptosis is characterized by the aberrant collapse of disulfide bonds in actin cytoskeleton proteins and F-actin. This study aims to explore the potential of disulfidptosis-related genes (DRGs) as biomarkers and targets for myocardial infarction (MI). Eight of the 24 DRGs differently expressed in the peripheral blood samples of MI patients compared to healthy people; five of the differently expressed DRGs (TLN1, SLC3A2, NDUFA11, FLNA and CD2AP) had tolerable diagnostic capabilities and were identified as the marker DRGs of MI; the marker DRGs played a vital role in immune response, inflammatory reaction, and energy metabolism. Some of the marker DRGs were correlated with several immune cells that were involved in MI. NV-128, ME-344 and metformin hydrochloride potentially target NDUFA11; IGN523 potentially target SLC3A2; and simufilam potentially target FLNA. DRGs might have potential in diagnosing MI, and targeting disulfidptosis might offer potential therapeutic value for MI.